Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > News > Anti-Cancer Candidate Shown to Be Well Tolerated

October 20th, 2006

Anti-Cancer Candidate Shown to Be Well Tolerated

Abstract:
Calando Pharmaceuticals, a leading siRNA therapeutics company and a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), announced results of a pilot safety-study using Calando’s lead siRNA therapeutic candidate in non-human primates.

Source:
businesswire

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

New blood test rapidly detects signs of pancreatic cancer May 17th, 2018

Elastic microspheres expand understanding of embryonic development and cancer cells May 15th, 2018

Nanomedicine -- Targeting cancer cells with sugars May 14th, 2018

NanoBio Announces Corporate Name Change to BlueWillow Biologics and Closes $10M Series A Financing: Move Reflects Focus on Advancing Several Intranasal Vaccines to Human Studies May 9th, 2018

Announcements

Supersonic waves may help electronics beat the heat May 18th, 2018

New blood test rapidly detects signs of pancreatic cancer May 17th, 2018

Disability Can Be a Superpower in Space Disabled astronauts offer unique solutions to emergencies in space May 17th, 2018

Deeper understanding of quantum chaos may be the key to quantum computers May 16th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project